Intellia EVP sells shares to cover RSU taxes

Intellia Therapeutics executive Eliana Clark reported an automatic share sale related to taxes.

Accepted by SEC EDGAR 01/07/2026 - 04:03 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Intellia Therapeutics executive Eliana Clark reported an automatic share sale related to taxes. A Form 4 shows that on January 5, 2026, the EVP and Chief Technical Officer sold 9,515 shares of Intellia Therapeutics common stock at $9.21 per share. The filing explains this was a mandatory “sell-to-cover” transaction to satisfy her tax withholding obligation upon the vesting of restricted stock units on January 1, 2026, and does not represent a volitional trade by the reporting person.

After this transaction, she beneficially owns 87,118 shares of Intellia common stock, including 1,264 shares acquired under the company’s 2016 Employee Stock Purchase Plan on December 31, 2025.

Insider Trade Summary

Net Seller: 9,515 shares

Net Sell 1 txn

Insider Clark Eliana

Role EVP, Chief Technical Officer

Sold 9,515 shs ($88K)

Share of Position Sold 9.8%

Type	Security	Shares	Price	Value
Sale	Common Stock	9,515	$9.21	$88K

Holdings After Transaction: Common Stock — 87,118 shares (Direct)

Holdings Before and After: Common Stock, 96,633 to 87,118 shares (Direct)

Other Insiders: 6 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.
2. F2. Includes 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the insider in this Intellia Therapeutics (NTLA) Form 4 filing?

The insider is Eliana Clark, who serves as EVP, Chief Technical Officer of Intellia Therapeutics, Inc.

How many Intellia Therapeutics shares did Eliana Clark sell and at what price?

The Form 4 reports that Eliana Clark sold 9,515 shares of Intellia Therapeutics common stock at a price of $9.21 per share on January 5, 2026.

Why were Intellia Therapeutics shares sold in this Form 4 transaction?

The filing states the sale represents a mandatory “sell-to-cover” transaction to satisfy the reporting person’s tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the reporting person.

How many Intellia Therapeutics shares does Eliana Clark own after this transaction?

Following the reported sale, Eliana Clark beneficially owns 87,118 shares of Intellia Therapeutics common stock.

Does Eliana Clark’s reported share ownership include stock purchased through an employee plan?

Yes. The filing notes that her holdings include 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2025.

Was this Intellia Therapeutics Form 4 sale a discretionary trade by the insider?

No. The explanation states the transaction was a mandatory sell-to-cover to pay tax withholding on RSU vesting and “does not represent a volitional trade” by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clark Eliana

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S(1)		9,515	D	$9.21	87,118(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.

2. Includes 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2025.

	James Basta, attorney-in-fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.